Stocks to Watch: Barnes & Noble, Gen-Probe (Update 1)
Updated with information about Barnes & Noble's deal with Microsoft, Hologic's acquisition of Gen-Probe.
The partnership includes a NOOK application for Windows 8, Barnes & Noble and Microsoft said.
Shares of Barnes & Noble soared 72.08% in premarket trading Monday to $23.54. The stock has fallen 5.52% year to date.
Microsoft shares ticked up 21 cents, or 0.66%, in premarket trading to $32.19. The stock has risen 23.19% year to date.
Shares of Gen-Probe rose 19.33% in premarket trading Monday to $82. The stock has risen 16.23% year to date.
Hologic shares increased 4.8% in premarket trading to $22.25. The stock has gained 21.25% year to date.
NYSE Euronext (NYX) said first-quarter adjusted earnings declined 32%.
The exchange saw a slowdown in trading, particularly in its derivatives trading unit, and was hit by costs associated with its failed merger with Germany's Deutsche Boerse .
Adjusted profit in the quarter was 47 cents a share; analysts were looking for 48 cents.
Humana(HUM) , the health care company, reported first-quarter earnings Monday of $248 million, or $1.49 a share, down from year-earlier earnings of $315 million, or $1.86 a share.
First-quarter earnings included a gain of 3 cents a share from previous medical claim reserves; year-earlier earnings included a gain of 31 cents a share.
Humana was expected by analysts to report first-quarter earnings of $1.52 a share.
Humana raised its full-year 2012 guidance to between $7.55 a share and $7.75 a share from a previous range of between $7.50 a share and $7.70 a share. Analysts were calling for earnings of $7.99 a share.
Shares of Humana fell 4.35% in premarket trading Monday to $84. The stock has risen 0.24% year to date.
Watson Pharmaceuticals (WPI) reported non-GAAP first-quarter earnings Monday of $208.8 million, or $1.64 a share, up from year-earlier earnings of $111.9 million, 89 cents.
Analysts were expecting first-quarter profit of $1.60 a share on revenue of $1.48 billion.
Shares of Watson Pharmaceuticals were flat in premarket trading on Monday. The stock has risen 26.22% year to date.
Watson Pharmaceuticals last week agreed to buy competitor Actavis for $5.6 billion.
Warner Chilcott (WCRX) , the drugmaker, is weighing options including a possible sale after receiving interest from strategic and private-equity buyers, according to people with knowledge of the matter, Bloomberg reported.
Shares of Warner Chilcott gained 15.86% in premarket trading Monday to $21.77.